Hiroshi Doi1, Kazuhiro Kitajima2, Kazuhito Fukushima3, Yusuke Kawanaka3, Miya Mouri3, Satoshi Yamamoto1, Reiichi Ishikura1, Tomonori Terada4, Kazuma Noguchi5, Shozo Hirota1. 1. Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 2. Department of Nuclear Medicine and PET Center, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. kitajima@med.kobe-u.ac.jp. 3. Department of Nuclear Medicine and PET Center, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 4. Department of Otolaryngology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 5. Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Abstract
PURPOSE: Our aim was to determine whether the maximum standardized uptake value (SUVmax) of the primary lesion demonstrated by [(18)F]-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is associated with the prognosis of maxillary sinus cancer. MATERIALS AND METHODS: The relationships of clinicopathological factors including age, T stage, N stage, histologic type, treatment strategy, and primary tumor SUVmax with progression-free (PFS) and overall (OS) survival were evaluated using the log-rank test and Cox method in 31 patients with maxillary sinus cancer before combined superselective intra-arterial chemotherapy using high-dose cisplatin with concurrent radiotherapy, or radiotherapy alone. RESULTS: The median duration of follow-up was 55.4 (range 9.7-72.6) months. PFS and OS of patients exhibiting a high SUVmax (≥16 and ≥17, respectively) for the primary tumor were significantly lower than those of patients for whom the primary tumor SUVmax was low (p = 0.0010 and p = 0.033, respectively). Multivariate analyses showed that T stage (p = 0.0049) and primary tumor SUVmax (p = 0.026) were independently prognostic of poorer PFS and that only primary tumor SUVmax (p = 0.049) was independently prognostic of poorer OS. CONCLUSION: SUVmax of the primary tumor determined by FDG-PET/CT before treatment could be a good surrogate marker for prognostication of maxillary sinus cancer.
PURPOSE: Our aim was to determine whether the maximum standardized uptake value (SUVmax) of the primary lesion demonstrated by [(18)F]-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is associated with the prognosis of maxillary sinus cancer. MATERIALS AND METHODS: The relationships of clinicopathological factors including age, T stage, N stage, histologic type, treatment strategy, and primary tumor SUVmax with progression-free (PFS) and overall (OS) survival were evaluated using the log-rank test and Cox method in 31 patients with maxillary sinus cancer before combined superselective intra-arterial chemotherapy using high-dose cisplatin with concurrent radiotherapy, or radiotherapy alone. RESULTS: The median duration of follow-up was 55.4 (range 9.7-72.6) months. PFS and OS of patients exhibiting a high SUVmax (≥16 and ≥17, respectively) for the primary tumor were significantly lower than those of patients for whom the primary tumor SUVmax was low (p = 0.0010 and p = 0.033, respectively). Multivariate analyses showed that T stage (p = 0.0049) and primary tumor SUVmax (p = 0.026) were independently prognostic of poorer PFS and that only primary tumor SUVmax (p = 0.049) was independently prognostic of poorer OS. CONCLUSION: SUVmax of the primary tumor determined by FDG-PET/CT before treatment could be a good surrogate marker for prognostication of maxillary sinus cancer.
Authors: Chad Tang; James D Murphy; Brian Khong; Trang H La; Christina Kong; Nancy J Fischbein; A Dimitrios Colevas; Andrei H Iagaru; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-21 Impact factor: 7.038
Authors: Andrew Davies; Carol Tan; Christos Paschalides; Sally F Barrington; Mike O'Doherty; Martin Utley; Tom Treasure Journal: Lung Cancer Date: 2006-11-03 Impact factor: 5.705
Authors: A Homma; T Sakashita; D Yoshida; R Onimaru; K Tsuchiya; F Suzuki; K Yasuda; H Hatakeyama; J Furusawa; T Mizumachi; S Kano; N Inamura; S Taki; H Shirato; S Fukuda Journal: Br J Cancer Date: 2013-11-05 Impact factor: 7.640